Senti Biosciences, INC

Senti Biosciences Holdings, Inc. announces a strategic merger with an affiliate of its largest stockholder, Celadon Partners, to spin off its Gene-Circuit pipeline, including SENTI-202, while retaining focus on Regulator Dial technology for future gene and cell therapies.

Senti Biosciences Holdings, Inc. announced the closing of a $10.0 million Senior Secured Convertible Note issuance to Celadon Partners SPV 24, with related agreements including a Guarantee and Voting Agreements.

Senti Biosciences reported Q1 2026 results, highlighting positive FDA feedback for SENTI-202 pivotal trial and a strategic financing agreement.

Senti Biosciences Holdings, Inc. announced a private placement of up to $40 million in senior secured convertible notes, with its largest stockholder, Celadon Partners, providing the initial $10 million.

Senti Biosciences, Inc. has completed its holding company reorganization, establishing Senti Biosciences Holdings, Inc. as the new public parent entity, with no material change to operations.

Senti Biosciences, Inc. announced plans for a tax-free holding company reorganization, converting existing shares into those of a new parent entity, Senti Biosciences Holdings, Inc., by April 16, 2026.

Senti Biosciences reports on Q1 2026, detailing a significant lease amendment with GeneFab, a reduction in operating expenses, and a subsequent financing agreement.

Senti Biosciences reports significant net losses and dwindling cash, raising substantial doubt about its going concern ability, while its partner halts a clinical trial due to toxicities.

Senti Biosciences reports increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite progress with SENTI-202 and recent capital raises.

Senti Biosciences reports a net loss of $14.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Senti Biosciences reports a net loss of $28.9 million for the third quarter of 2024, alongside updates on clinical development and strategic partnerships.

Senti Biosciences' second quarter 2024 results show a net loss of $11.2 million, with management expressing substantial doubt about the company's ability to continue as a going concern.

Senti Biosciences Holdings, Inc. has filed an amendment to its 2025 annual report, providing detailed information on its directors, executive officers, corporate governance, and executive compensation.

Senti Biosciences reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite positive Phase 1 clinical data for its lead CAR-NK cell therapy, SENTI-202.

Senti Biosciences details its financial performance for 2024 and provides updates on its clinical programs, including progress with SENTI-202 and SN301A.

Senti Biosciences has filed an amendment to its 2023 annual report to include required information regarding directors, executive compensation, and other corporate governance matters.

Senti Biosciences partners with Celest Therapeutics to advance clinical development of SENTI-301A in China, with first patient enrollment expected in the first half of 2024.

Kanya Rajangam, President & Chief Medical & Development Officer of Senti Biosciences, reported a disposition of 1,384 common shares for tax withholding purposes.

Senti Biosciences CEO Timothy K Lu reported a tax-related disposition of 4,191 common shares to cover restricted stock unit vesting obligations, not an open market sale.

Senti Biosciences, Inc. Director Bryan Daniel Baum was granted 43,900 stock options with an exercise price of $1.95, vesting over three years starting July 18, 2025.

Senti Biosciences, Inc. Director James J. Collins was granted 21,950 stock options with an exercise price of $2.05, vesting over time.

Senti Biosciences, Inc. Director Feng Hsiung was granted 21,950 stock options with an exercise price of $2.05, vesting over one year or by the 2026 Annual Meeting, as disclosed in a recent SEC Form 4 filing.

Senti Biosciences, Inc. Director Fran Schulz was granted 21,950 stock options with an exercise price of $2.05, aligning her interests with shareholder value.

Senti Biosciences has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Senti Biosciences will hold its 2025 Annual Meeting of Stockholders virtually on June 25, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Senti Biosciences is holding a special meeting to seek stockholder approval for a share issuance related to a recent private placement and to amend its equity incentive plan.

Senti Biosciences has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Senti Biosciences is holding its 2024 Annual Meeting of Stockholders virtually on July 10, 2024, to vote on key proposals including officer exculpation, a reverse stock split, and ratification of KPMG LLP as the independent auditor.

Celadon Partners SPV 35 Limited is set to acquire Senti Biosciences' Gene-Circuit pipeline, including SENTI-202, through a merger agreement, with Senti Biosciences Holdings, Inc. remaining a public entity.

Celadon Partners has increased its stake in Senti Biosciences to 54.6% through a significant investment in convertible notes, signaling a strategic shift for the gene therapy company.

Bayer HealthCare LLC and associated entities filed an amended Schedule 13D confirming a 17.82% beneficial ownership stake in Senti Biosciences, Inc.

New Enterprise Associates and affiliated entities report a decrease in their beneficial ownership of Senti Biosciences, Inc. common stock to 12.1% due to an increase in outstanding shares.

Celadon Partners, a significant shareholder in Senti Biosciences, is engaged in preliminary discussions for a potential $10 million convertible bond financing and strategic transactions.

Celadon Partners, holding 45% of Senti Biosciences, is in discussions for a potential financing deal and board representation, signaling strategic changes.

Nantahala Capital Partners Limited Partnership has filed an amended Schedule 13G, reporting a beneficial ownership of 1.9% in Senti Biosciences, Inc. as of March 31, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed an 8.12% beneficial ownership stake in Senti Biosciences, Inc., including shares acquirable via warrants.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed an 8.12% beneficial ownership stake in Senti Biosciences, Inc., including shares acquirable via warrants.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.99% in Senti Biosciences, Inc.'s Class A Common Stock as of March 31, 2025.

8VC Fund I, L.P., 8VC Entrepreneurs Fund I, L.P., 8VC GP I, LLC, and Joe Lonsdale have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 253,755 shares, representing 1% of Senti Biosciences, Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have jointly disclosed a 9.99% beneficial ownership stake in Senti Biosciences, Inc.'s Class A Common Stock, held for investment purposes.